Valuation
- Market cap
- 77,146,000
- Revenue TTM
- $0
- Net income TTM
- $-8,950,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 33,739
- Avg volume
- 71,918
- Day's range
- $1.36 – $1.48
- Shares out
- 52,480,000
- Stochastic %K
- 87%
- Beta
- 0.05
- Analysts
- Strong Sell
- Price target
- $8.33
Company profile
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in...
Show more
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 44 20 7495 2379
- Website
- https://okyopharma.com
- Address
- 35a Albemarle St, Floor 2, London, United Kingdom
Latest news
No headlines yet.
